

## Special Issue

# Cell-Based Drugs in Cancer Immunotherapy

### Message from the Guest Editor

The development of Advanced Therapy Medicinal Products (ATMPs), particularly within the field of cellular therapies, is advancing at an astonishing rate. Cellular therapies are clearly becoming the next generation of pharmaceutical drugs and are already greatly complementing small molecules and biologicals. The first notable regulatory advance came in 2010, when Sipuleucel-T, a cell-based cancer immunotherapy, was approved by the FDA for the treatment of prostate cancer. The second major breakthrough both in a therapeutic and regulatory sense was the 2017 approval of tisagenlecleucel, a CAR-T cell therapy, for the treatment of B cell acute lymphoblastic leukemia. Since then, several ingenious approaches have been used to further advance the efficacy of cellular immunotherapy drugs by manipulating or engineering their major active substance, the living cell.

---

### Guest Editor

Dr. Urban Švajger

1. Department for Therapeutic Services, Slovenian Institute for Transfusion Medicine, SI-1000 Ljubljana, Slovenia
2. Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia

---

### Deadline for manuscript submissions

closed (30 April 2022)



## International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/64593](https://mdpi.com/si/64593)

*International Journal of  
Molecular Sciences*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[ijms@mdpi.com](mailto:ijms@mdpi.com)

[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)





# International Journal of Molecular Sciences

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
ijms](https://mdpi.com/journal/ijms)



## About the Journal

### Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

---

### Editor-in-Chief

Prof. Dr. José L. Quiles  
Department of Physiology, Institute of Nutrition and Food Technology  
"Jose Mataix", Biomedical Research Center, University of Granada,  
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)